Search Results for "sodium sulfate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for sodium sulfate. Results 1 to 3 of 3 total matches.

Sodium Sulfate-Based Tablets (Sutab) for Colonoscopy Preparation

   
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021  (Issue 1619)
Sodium Sulfate-Based Tablets (Sutab) for Colonoscopy Preparation ...
The FDA has approved an oral tablet formulation of sodium sulfate, magnesium sulfate, and potassium chloride (Sutab – Braintree) for colon cleansing prior to colonoscopy in adults. A sodium sulfate-based oral solution (Suprep) has been available in the US since 2010. Sutab is the second tablet formulation to be approved for bowel cleansing prior to colonoscopy; a sodium phosphate-based tablet (OsmoPrep) was approved earlier.
Med Lett Drugs Ther. 2021 Mar 8;63(1619):33-6 |  Show IntroductionHide Introduction

Suflave — A Low-Volume Colonoscopy Preparation

   
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023  (Issue 1685)
contains PEG 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride ...
The FDA has approved Suflave (Sebela/Braintree), a low-volume polyethylene glycol (PEG)- and sulfate-based product for cleansing of the colon prior to colonoscopy in adults. Other oral colonoscopy preparations available in the US are listed in Table 2. Suflave is marketed as tasting better than other products.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):148-51   doi:10.58347/tml.2023.1685b |  Show IntroductionHide Introduction

Treatment of Allergic Rhinitis and Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • Mar 31, 2025  (Issue 1725)
-generation AH or intranasal AH4 ▶ Oral 2nd-generation AH + pseudoephedrine5 ▶ Intranasal cromolyn sodium ...
Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2025 Mar 31;67(1725):49-56   doi:10.58347/tml.2025.1725a |  Show IntroductionHide Introduction